AMD

In an interview with David Hutton of Ophthalmology Times, Ash Abbey, MD, discusses the Phase 3 LUGANO trial for EYP-1901 in treating wet age-related macular degeneration. Abbey discusses the trial’s non-inferiority objectives, treatment schedule, patient outcomes like reduced treatment burden, and anatomical stability. Patient interest is high, particularly among those wanting fewer injections, though recruiting treatment-naive patients may be challenging. If results are favorable, potential FDA approval could occur within 3 to 4 years.

Researchers receive $6.4 million grant from NEI to seek new treatment for blindness-causing diseases.

CBNS, such as turmeric, are natural anti-inflammatory and antioxidant agents that may confer benefits against AMD.

According to the company, the second Phase 3 LUCIA pivotal trial first patient dosing is expected by end of 2024 with topline data anticipated in 2026.

According to a study presented at the American Academy of Ophthalmology’s annual meeting in Chicago, investigational treatment reduced vision loss and protected key structures in the eye essential for vision.

The subretinal drusenoid deposits may serve as a biomarker of serious heart disease.

According to the company, the axitinib injectable suspension achieved all primary and secondary outcomes and maintained stable visual acuity and anatomical control over 9 months.

Related macular dystrophies include Sorsby’s fundus dystrophy, Doyne honeycomb macular dystrophy, and autosomal dominant radial drusen.

The company made notable hires in its biometrics, clinical operations, and market access departments.

The data were presented at the Keystone Symposium Targeting Dry Age-related Macular Degeneration: Pathophysiology and Emerging Therapies.

Socioeconomic factors have long been a looming issue in various health outcomes. A team of researchers from Shanghai Jiao Tong University School of Medicine and Fudan University set out to review the impact of socioeconomic status inequality on the incidence of AMD.

Oral gildeuretinol demonstrated a clinically meaningful reduction in the geographic atrophy lesion growth rate at 24 months, supporting additional clinical development. SAGA topline data has been accepted as a late breaker at the 128th annual meeting of the American Academy of Ophthalmology, being held October 18-21 in Chicago.

4D Molecular Therapeutics has announced data based on the longest interim follow-up from Phase 1/2 PRISM clinical trial and 4FRONT Phase 3 study design.

Diana Do, MD, spoke with the Ophthalmology Times team about her presentation at the Retina Society meeting focusing on Population Pharmacokinetic Modeling and Simulation of Ocular Clearance for Aflibercept 8 mg and 2 mg.

Meeting in Stockholm provides education, updates, and a taste of culture.

Visual acuity and macular anatomy were maintained, with some changes in fluid management.

Research by investigators at Trinity College in Dublin shows how the gene therapy conferred significant benefit in animal models, and in human cells derived from people with glaucoma.

Data from this trial will be reported ahead of AAO 2024 in Chicago, Illinois.

The next step for the research likely will focus on determining whether blocking GSK3 can reverse existing AMD damage, potentially leading to new treatment options.

According to the company, the pre-clinical safety and efficacy studies of its product have yielded positive results in 3 internationally recognized labs in India, Singapore and the United States.

Pearls for implanting the port delivery device with ranibizumab.

According to the company, the FDA approval strengthens its biosimilar position in the US market.

LUBT010 is a ranibizumab biosimilar to Lucentis and the study achieved its primary endpoint